AC220

Synthesis is established with a mission to provide drug discovery researchers with access to the world’s most up-to-date library of kinase and small molecule inhibitors for research use. Our founders include kinase scientists and expert synthetic chemists, and under their guidance we believe we have created the world's largest library of potent, pure and research-relevant kinase inhibitors for use as reference compounds.